Adipose-derived mesenchymal stem cell-conditioned medium and proliferation of intestinal stem cells in mesenteric

Ryo Yamamoto1, Sayuri Suzuki1, Koichiro Homma2

  • 1Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.

Scientific Reports
|July 4, 2026
PubMed

Insights

Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM) protects intestinal stem cells from ischemia-reperfusion injury. MSC-CM therapy preserved intestinal stem cells and promoted healing, offering a potential treatment for bowel damage.

Area of Science:

  • Regenerative Medicine
  • Gastroenterology
  • Stem Cell Biology

Background:

  • Mesenteric ischemia often leads to bowel necrosis due to reperfusion injury, with no effective therapies currently available.
  • Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM) is a promising regenerative therapy for organ damage.
  • The therapeutic potential of MSC-CM in mitigating intestinal ischemia-reperfusion injury requires further investigation.

Purpose of the Study:

  • To investigate the therapeutic effects of MSC-CM on intestinal tissue injury induced by ischemia and reperfusion.
  • To evaluate the impact of MSC-CM on intestinal stem cell preservation and related molecular pathways.

Main Methods:

  • Mice underwent 60-minute mesenteric artery occlusion (ischemia) or ischemia followed by 60-minute reperfusion.
  • The MSC-CM group received MSC-CM intravenously after ischemia-reperfusion.
  • Immunofluorescence staining (caspase-3, LGR5) and quantitative PCR (LGR5, Notch1, Jagged 1, Hes1, DLL1-4) were performed on distal ileum tissues.

Main Results:

  • Ischemia damaged the epithelial layer; reperfusion induced apoptosis. MSC-CM preserved cells at the crypt base, identified as intestinal stem cells.
  • MSC-CM administration significantly increased LGR5 expression compared to ischemia and reperfusion groups.
  • The MSC-CM group showed elevated Notch1 and Jagged 1 mRNA expression, indicating potential involvement in stem cell signaling.

Conclusions:

  • MSC-CM effectively preserves intestinal stem cells at the crypt of villi following ischemia-reperfusion injury.
  • MSC-CM treatment upregulates key components of the Notch signaling pathway (Notch1, Jag1), suggesting a mechanism for intestinal protection.
  • MSC-CM represents a potential therapeutic strategy for managing intestinal damage caused by mesenteric ischemia and reperfusion.